Humalog and NovoLog insulin are high-risk medications that require both therapeutic monitoring to ensure optimal short- and long-term outcomes and sufficient counseling for the prevention of adverse events such as hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.